Please assess the completion status of the following clinical trial:

Trial Title: Novel Agents for Treatment of High-risk COVID-19 Positive Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria~* Age ≥18 years~* Laboratory-confirmed SARS-CoV-2 infection within the past 7 days or the presence of symptoms or physical examination signs providing high probability of COVID-19 disease~* Patients must have adequate organ and marrow function measured within the last 6 months~* Subjects must have at least one of the following high-risk features for clinical deterioration:~  * Hypertension~ * Diabetes Mellitus~ * Moderate to severe Chronic Obstructive Pulmonary Disease, Emphysema, Cystic Fibrosis, or Asthma~ * Cancer patients who have received any immunosuppressive drugs within a year from enrollment~ * Sickle Cell disease or thalessemia~ * Age \> or = 50~ * BMI \> or = 30~ * Living in a nursing home or long-term facility~ * Underlying serious heart condition as determined by the treating physician~ * Immunocompromised subject as defined by the treating physician or COVID-19 Telehealth Treatment Team~Exclusion Criteria~* Severe or life threating COVID~* Weight less than 45 kg.~* Pregnant or breast-feeding females~* Subjects on dialysis or with creatinine clearance \< 45 ml/min~* Existing DMID Toxicity Scale for Determining Severity of Adverse Events grade 3 or greater hepatic failure~* Previously documented moderate or severe retinopathy or macular degeneration~* Uncontrolled Seizure disorder~* Prolonged QT, defined as QTc ≥470 milliseconds for men and as QTc ≥480 for women using Bazett's formula~* Known allergy to artesunate, artemisia annua, hydroxychloroquine, macrolides, 4-aminoquinolines, camostat mesilate, or other agents to be used in the trial.~* Currently receiving any study medications for other indications~* Concurrent use of medication that would cause drug-drug interactions~* Patients with psychiatric illness/social situations that would limit compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Arm C: Ivermectin (Type: EXPERIMENTAL): Ivermectin
- Arm D: Camostat Mesilate (Type: EXPERIMENTAL): Camostat Mesilate
- Arm E: Artemesia annua (Type: EXPERIMENTAL): Artemesia annua tea or coffee
- Arm F: Artesunate (Type: EXPERIMENTAL): Artesunate

Based on this trial design, predict the completion outcome and termination type (if applicable).